会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 43. 发明授权
    • Method and apparatus for monitoring ingestion of medications using an implantable medical device
    • 用于使用可植入医疗装置监测摄取药物的方法和装置
    • US07876228B2
    • 2011-01-25
    • US12174594
    • 2008-07-16
    • Mark W. KrollAlan B. Vogel
    • Mark W. KrollAlan B. Vogel
    • G08B23/00
    • G06F19/3456A61B5/0031A61B5/076A61B5/1116A61B5/1123A61B5/4205A61B5/4833A61B5/4839A61B7/008A61B90/90A61B90/98A61B2562/0219A61N1/365G06F19/00Y10S128/903
    • An implantable medical device, such as a pacemaker or implantable cardioverter defibrillator (ICD), is configured to automatically detect ingestion of medications to verify that prescribed medications are taken in a timely manner and at the correct dosage. Briefly, individual pills are provided with miniature radio frequency identification (RFID) devices capable of transmitting RFID tag signals, which identify the medication contained within the pill and its dosage. The implanted device is equipped with an RFID transceiver for receiving tag signals from a pill as it is being ingested. The implanted system decodes the tag to identify the medication and its dosage, then accesses an onboard database to verify that the medication being ingested was in fact prescribed to the patient and to verify that the correct dosage was taken. Warning signals are generated if the wrong medication or the wrong dosage was taken. Therapy may also be automatically adjusted. Non-RF-based ID devices are also described, which instead transmit ID data via biphasic current pulses.
    • 诸如起搏器或植入式心律转复除颤器(ICD)的可植入医疗装置被配置为自动检测药物的摄取以验证是否及时以正确剂量服用规定的药物。 简而言之,单独的药丸配备有能够发送RFID标签信号的微型射频识别(RFID)设备,其识别药物中所含的药物及其剂量。 植入装置配备有RFID收发器,用于在被摄取时从药片接收标签信号。 植入的系统解码标签以识别药物及其剂量,然后访问车载数据库以验证被摄取的药物实际上是对患者进行处方,并验证是否采取了正确的剂量。 如果使用了错误的药物或错误的剂量,就会产生警告信号。 治疗也可以自动调整。 还描述了基于非RF的ID设备,其代替通过双相电流脉冲发送ID数据。
    • 46. 发明授权
    • Automatic system for determining bi-ventricular pacing responders
    • 用于确定双心室起搏应答者的自动系统
    • US07689280B1
    • 2010-03-30
    • US11290938
    • 2005-11-29
    • Mark W. KrollEuljoon Park
    • Mark W. KrollEuljoon Park
    • A61N1/08
    • A61N1/368A61N1/3627A61N1/36521A61N1/3684A61N1/37258
    • A method of predicting a patient's response to multi-chamber pacing by implanting at least three sensing electrodes, measuring across at least two different impedance vectors of the heart via the three electrodes to obtain at least two impedance signals, and evaluating the at least two impedance signals for indications of contractile dysynchrony. Contractile dysynchrony indicates that the patient is likely to have a positive response to multi-chamber pacing. Also an implantable cardiac stimulation device with an implantable housing, a stimulation pulse generator positioned within the housing, at least two implantable leads, and a controller communicating with the pulse generator to induce the generator to deliver therapeutic stimulation to a patient's heart. The leads are arranged to measure a physiological parameter along at least two different spatial orientations. The controller evaluates relative timing of the physiological parameters along the different orientations for indications of contractile synchrony of the patient's heart.
    • 一种通过植入至少三个感测电极来预测患者对多室起搏的反应的方法,通过三个电极测量心脏的至少两个不同阻抗向量,以获得至少两个阻抗信号,并评估至少两个阻抗 用于收缩异常现象的信号。 收缩异常表示患者可能对多室起搏有积极的反应。 还有一种具有可植入壳体的可植入心脏刺激装置,位于壳体内的刺激脉冲发生器,至少两个可植入引线,以及与脉冲发生器通信以使发生器向患者心脏输送治疗刺激的控制器。 引线布置成沿着至少两个不同的空间取向测量生理参数。 控制器评估沿着不同方向的生理参数的相对时间,用于指示患者心脏的收缩同步。
    • 47. 发明授权
    • Direct current fibrillator
    • 直流纤颤器
    • US07684870B1
    • 2010-03-23
    • US11282172
    • 2005-11-18
    • Mark W. KrollJ. Christopher MoulderGabriel A. Mouchawar
    • Mark W. KrollJ. Christopher MoulderGabriel A. Mouchawar
    • A61N1/39
    • A61N1/385
    • An implantable cardiac device to induce fibrillation in the heart of a patient to allow testing of the defibrillation capability of the device. The device induces fibrillation using a direct current across the heart. The shock to the heart may be applied in a method to minimize discomfort to the patient. The heart is monitored during application of the shock. The voltage of shock at the heart is gradually increased until fibrillation is induced. Once the fibrillation is detected the shock may be stopped. This results in a minimized voltage level and duration for the shock to the heart, thereby diminishing pain and discomfort to the patient.
    • 一种植入式心脏装置,用于在患者的心脏中诱导原纤维化,以允许测试该装置的除颤能力。 该装置使用穿过心脏的直流电导致纤维颤动。 心脏的震荡可以用于最小化患者不适的方法。 在应用冲击期间监测心脏。 心脏的休克电压逐渐增加,直到引发颤动。 一旦检测到颤动,可能会停止休克。 这导致对心脏的休克的最小电压电平和持续时间,从而减轻患者的疼痛和不适。